Exploratory study on effectiveness and safety of long-term administration of Rikkunshito for improvement of anorexia and quality of life in patients with Parkinson's disease accompanied by apathy.

Exploratory study on effectiveness and safety of long-term administration of Rikkunshito for improvement of anorexia and quality of life in patients with Parkinson's disease accompanied by apathy. - Exploratory study on effectiveness and safety of long-term administration of Rikkunshito for improvement of anorexia and quality of life in patients with Parkinson's disease accompanied by apathy.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030857

Enrollment

Registered

2018-01-17

Start date

2018-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

Parkinson&#39

s disease normal treatment + Rikkunshito treatment group In addition to the usual treatment of Parkinson &#39

s disease, Rikkunshito 6 months combined use Parkinson&#39

s disease treatment group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who satisfy all of the following items are targeted. (1) Patients diagnosed with Parkinson's disease (2) Hoehn-Yahr Classification I to III patients (conducted within 6 months) (3) Patients with CNAQ of 28 or less (4) Patients with a motivation score of 16 or more (5) Age: 50 years old and over 90 years old (6) Medical examination classification: outpatient (7) Patients who obtain document consent from the principal However, (3) (4) is conducted twice at intervals of 4 weeks. (3) are patients who satisfy the criteria in both cases, (4) subjects who meet the criteria twice and whose difference in score is within 5 points.

Exclusion criteria

Exclusion criteria: Patients applicable to any one of the following items are excluded. (1) Patients complicated of dementia (patients with MoCA-J of 25 or less) (2) Patients with depression, psychiatric symptoms (3) Patients with abnormalities judged to require treatment by brain MRI (performed within 6 months) (4) Patients who can not orally administer (5) Patients who took herbal medicine within the first month before the start of the study (6) Patients who can not discontinue combination use prohibited medicine during the observation period from two weeks before the start of the study (7) Patients complicated of serious complications (heart, liver, kidney function disorder, hematopoietic disorder, malignant tumor etc.) or other diseases judged to affect life (8) Patients allergic to traditional Chinese medicine (9) Patients judged unsuitable by research researcher or research sharing doctor However, MoCA-J of (1) is carried out twice at intervals of 4 weeks, and patients who were 25 points or less at once are excluded.

Design outcomes

Primary

Measure	Time frame
1) CNAQ 2) VAS	—

Countries

Japan

Contacts

Public ContactKoji Yakabi

Saitama Medical Center, Saitama Medical University Department of Gastroenterology and Hepatology

kjyakabi@saitama-med.ac.jp049-228-3598

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Exploratory study on effectiveness and safety of long-term administration of Rikkunshito for improvement of anorexia and quality of life in patients with Parkinson&#39;s disease accompanied by apathy.